Clinical trials: Pancreas Tumor
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Adenocarcinoma
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.
- Trial name
- NCT00892242
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced …
- Trial name
- ARTIA-Pancreas (NCT05764720)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 134 people
- Sponsor
- Varian, a Siemens Healthineers Company
Pancreatic Cancer
Pancreatic Resection in Fit Octogenarians With Nonmetastatic Pancreatic Cancer
This study looks at how different treatment approaches affect survival in older people with pancreatic cancer that has not spread to other parts of the body.
- Trial name
- PRONPaC (NCT07542782)
- Testing
- All types of surgical tumor resection procedures with curative intent, No surgical resection
- Where
- Germany
- Volunteers
- 2,048 people
- Sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
Metastatic Pancreatic Cancer
Gemcitabine (GFF) in Patients With Pancreatic Cancer
The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).
- Trial name
- GFF (NCT00919282)
- Testing
- gemcitabine, folinic acid, 5-FU
- Where
- Germany
- Volunteers
- 78 people
- Sponsor
- CONKO-Studiengruppe
Cancer, Pancreas
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
This is an open-label, multi-center phase II study of erlotinib in patients with metastatic or locally advanced, unresectable pancreatic cancer who have received up to one line of gemcitabine based chemotherapy.
- Trial name
- NCT00497224
- Testing
- Erlotinib
- Where
- 5 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Neoplastic Cells, Circulating
The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in pancreatic cancer could play an important role in…
- Trial name
- NCT02406846
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Pancreatic Cancer
Investigator-initiated Clinical Trial of MIKE-1
To evaluate the safety and tolerability of Am80（Generic name: Tamibarotene, Development code: MIKE-1） in combination with gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with unresectable pancreatic cancer and to…
- Trial name
- MIKE-1 (NCT05064618)
- Testing
- Am80, Gemcitabine, nab-Paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 55 people
- Sponsor
- Nagoya University
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
- Trial name
- NCT06984562
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Neuroendocrine Tumor
Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
The purpose of the protocol is to estimate the progression-free survival (PFS) rate in subjects diagnosed with PanNET, according to investigator assessment, at 24 months after treatment initiation with lanreotide 120 mg every 28…
- Trial name
- PanNET (NCT03947762)
- Where
- 46 sites in Portugal, Spain
- Volunteers
- 54 people
- Sponsor
- Ipsen
Treatment Related Cancer
Pancreatic Cyst Ablation With a Monopolar Radiofrequency Ablation Probe
Pancreatic cysts (A cyst is a thin walled cavity containing fluid) were rarely reported previously, but have been on a rise due to advanced imaging for evaluating pancreatic lesions or other medical reasons has increased…
- Trial name
- NCT04253249
- Where
- United States
- Sponsor
- Baylor College of Medicine
Pancreatic Cancer, Jaundice
The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease
Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC.
- Conditions
- Pancreatic Cancer, Jaundice, Abdominal Neoplasm
- Trial name
- NCT06276738
- Testing
- LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
This phase II trial studies the side effects and how well pembrolizumab in combination with pelareorep work in treating patients with pancreatic cancer that has spread to other parts of the body.
- Conditions
- Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT03723915
- Testing
- Pembrolizumab, Wild-type Reovirus
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Pancreatic Cancer
Gene Expression in Pancreatic Cancer
Pancreatic cancer is a lethal disease. The 1-year and 5-year survival rate is approximately 20% and <5% respectively. The treatment options available are limited.
- Trial name
- NEOPANC-01 (NCT03531125)
- Testing
- Endoscopic Ultrasound, Pancreaticoduodenectomy
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- University of Oxford
Pancreatic Neoplasm
Core Biopsy Endo Sonography Study Evaluation of the Significance of the Pro-core® Needle
The study is designed to evaluate the diagnostic accuracy of a new designed endoscopic ultrasonography (EUS) Core biopsy aspiration needle in comparison to a conventional EUS aspiration needle in GI-tumors.
- Trial name
- COS (NCT02181140)
- Testing
- EUS guided FNA and fine needle punction
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pancreas Cancer
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence…
- Trial name
- PROTECT-PANC (NCT06228599)
- Testing
- Treatment Plan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Cystic Fibrosis, Pulmonary Fibrosis
Role of Genetic Factors in the Development of Lung Disease
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.
- Conditions
- Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma
- Trial name
- NCT00001532
- Where
- 2 sites in United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.